Answers are grounded in this paper and cite their sources.
Ischemia/reperfusion (I/R) injury involves multiple interconnected mechanisms, including mitochondrial permeability transition pore opening and ferroptosis, whereas calcium overload and reactive oxygen species generation act as upstream injury signals rather than independent forms of regulated cell death. Cuproptosis is, at present, a weakly evidenced emerging candidate rather than a core mechanism on par with ferroptosis. Rather than centring cuproptosis, this review proposes a falsifiable metabolic-susceptibility framework and grades the existing evidence honestly. Its central premise is the dependence of cuproptosis on mitochondrial respiration and lipoylated metabolic proteins. During ischemia, suppression of pyruvate dehydrogenase (PDH) activity and oxidative metabolism may reduce cuproptosis susceptibility without necessarily diminishing DLAT lipoylation. During reperfusion, partial recovery of mitochondrial metabolism may create permissive conditions for copper-dependent proteotoxicity against a dynamically evolving background of oxidative stress, calcium dysregulation, and inflammation. This proposed transition remains hypothetical, as direct time-resolved evidence is limited and neither uniform susceptibility nor synchronized cuproptosis activation has been established. The framework predicts greater susceptibility in cells retaining active mitochondrial respiration than in glycolysis-dominant populations, while recognizing that metabolic plasticity during I/R precludes fixed cell-type assignments and requires functional validation beyond transcriptomic profiling. We propose an under-recognised Fe-Cu-S paradox as a central insight, define the “composite phenotype” explicitly as a hypothesis, and provide an orthogonal validation strategy. We further highlight a marker problem: Dihydrolipoamide S-Acetyltransferase (DLAT), ferredoxin 1, lipoic acid synthetase and pyruvate dehydrogenase are mitochondrial metabolic proteins whose changes cannot, alone, distinguish mitochondrial dysfunction from cuproptosis; the only relatively specific execution marker is copper-dependent, chelation-reversible DLAT disulfide oligomerisation. Organ evidence is graded into tiers A/B/C, and perioperative/critical-care translation is confined to proof-of-concept.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: